Search research articles
Contact Us
Filters
Showing results (11-20 of 30) with videos related to
Page
of 3
Sort By:
JAMA
|
October 4, 2022
Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial
Keith S Kaye, Adam Belley, Philip Barth, et al.
Diagnostic Microbiology and Infectious Disease
|
November 29, 2016
Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus
Debora Sweeney, Dean L Shinabarger, Francis F Arhin, et al.
Antimicrobial Agents and Chemotherapy
|
July 23, 2008
Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus
Adam Belley, Eve Neesham-Grenon, Francis F Arhin, et al.
The Journal of Antimicrobial Chemotherapy
|
April 17, 2009
Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium
Geoffrey A McKay, Sylvain Beaulieu, Francis F Arhin, et al.
Antimicrobial Agents and Chemotherapy
|
May 26, 2010
Assessment of oritavancin serum protein binding across species
Francis F Arhin, Adam Belley, Geoffrey McKay, et al.
The Journal of Antibiotics
|
January 23, 2023
Impact of surfactants and other body fluids on in vitro activity of a novel β-lactamase inhibitor enmetazobactam in combination with cefepime against clinical isolates of Klebsiella pneumoniae
Alina Nussbaumer-Pröll, Sabine Eberl, Adam Belley, et al.
Journal of Global Antimicrobial Resistance
|
May 9, 2024
Evaluation of the activity of cefepime/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates
Ian Morrissey, Stephen Hawser, Nimmi Kothari, et al.
Journal of Clinical Microbiology
|
June 7, 2019
Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam
Adam Belley, Michael D Huband, Kelley A Fedler, et al.
Antimicrobial Agents and Chemotherapy
|
September 30, 2010
Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing
Adam Belley, Geoffrey A McKay, Francis F Arhin, et al.
Journal of Clinical Microbiology
|
August 19, 2025
Establishing the reference broth microdilution MIC method for cefepime-taniborbactam
Adam Belley, Susan M Cusick, Dan C Pevear, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 30) with videos related to
Sort By:
Page
of 3
JAMA
|
October 4, 2022
Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial
Keith S Kaye, Adam Belley, Philip Barth, et al.
Diagnostic Microbiology and Infectious Disease
|
November 29, 2016
Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus
Debora Sweeney, Dean L Shinabarger, Francis F Arhin, et al.
Antimicrobial Agents and Chemotherapy
|
July 23, 2008
Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus
Adam Belley, Eve Neesham-Grenon, Francis F Arhin, et al.
The Journal of Antimicrobial Chemotherapy
|
April 17, 2009
Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium
Geoffrey A McKay, Sylvain Beaulieu, Francis F Arhin, et al.
Antimicrobial Agents and Chemotherapy
|
May 26, 2010
Assessment of oritavancin serum protein binding across species
Francis F Arhin, Adam Belley, Geoffrey McKay, et al.
The Journal of Antibiotics
|
January 23, 2023
Impact of surfactants and other body fluids on in vitro activity of a novel β-lactamase inhibitor enmetazobactam in combination with cefepime against clinical isolates of Klebsiella pneumoniae
Alina Nussbaumer-Pröll, Sabine Eberl, Adam Belley, et al.
Journal of Global Antimicrobial Resistance
|
May 9, 2024
Evaluation of the activity of cefepime/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates
Ian Morrissey, Stephen Hawser, Nimmi Kothari, et al.
Journal of Clinical Microbiology
|
June 7, 2019
Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam
Adam Belley, Michael D Huband, Kelley A Fedler, et al.
Antimicrobial Agents and Chemotherapy
|
September 30, 2010
Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing
Adam Belley, Geoffrey A McKay, Francis F Arhin, et al.
Journal of Clinical Microbiology
|
August 19, 2025
Establishing the reference broth microdilution MIC method for cefepime-taniborbactam
Adam Belley, Susan M Cusick, Dan C Pevear, et al.
Page
of 3